NNC0114-0006 + liraglutide

A combination therapy of **NNC0114-0006** (an anti-interleukin-21 monoclonal antibody) and **liraglutide** (a glucagon-like peptide-1 receptor agonist). NNC0114-0006 acts as an immunomodulatory agent, targeting and inhibiting interleukin-21 to reduce the autoimmune destruction of pancreatic beta cells. Liraglutide is a GLP-1 receptor agonist that enhances insulin secretion and improves beta-cell function. The combination is being developed as a potential disease-modifying intervention for **newly diagnosed type 1 diabetes**, aiming to preserve endogenous insulin production and beta cell function by both immune modulation and metabolic support[1][2][3][4].

Other names

anti-IL-21 + liraglutideanti-interleukin-21 monoclonal antibody + liraglutide